Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.75 |
| ▸ | DRD3 | P35462 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 4/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206503 | 0.92 | DRD2 (0.78) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL1255253 | 0.92 | DRD2 (0.78) | DRD2DRD3HTR1AADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL8980706 | 0.91 | DRD2 (0.76) | DRD2DRD3HTR1AADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL11651993 | 0.91 | DRD2 (0.76) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL8121554 | 0.90 | HTR1A (0.77) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL6526368 | 0.87 | DRD2 (0.85) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL8957265 | 0.87 | DRD2 (0.69) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL3261221 | 0.86 | DRD2 (1.00) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL31060769 | 0.86 | DRD2 (1.00) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL8363314 | 0.86 | DRD2 (0.77) | DRD2DRD3HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109280030-B | Benzazaylalkyl aryl piperazine derivative and application thereof in preparing medicines | 江苏恩华药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-109280030-A | Benzene a pair of horses going side by side azepine alkylaryl bridged piperazine derivatives and application in medicine preparation | 江苏恩华药业股份有限公司 | 2019-01-29 | — | — | CN | disclosed |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2285373-A2 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2219648-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-7723343-B2 | Adenosine A2A receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7691869-B2 | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| WO-2010036395-A2 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | CENOMED BIOSCIENCES, LLC (US) | 2010-04-01 | — | — | WO | disclosed |
| CN-101652067-A | Adenosine A2AReceptor antagonists | KING PHARMACEUTICALS RES & DEV | 2010-02-17 | — | — | CN | disclosed |
| US-4336382-A | ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1982-06-22 | — | — | US | disclosed |
| US-4329289-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-05-11 | — | — | US | disclosed |
| US-4314085-A | Intermediates for preparing adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4304721-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-12-08 | — | — | US | disclosed |
| US-4301300-A | ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1981-11-17 | — | — | US | disclosed |
| US-4285873-A | ANTIANDROGENS | HOFFMANN-LA ROCHE INC. (US) | 1981-08-25 | — | — | US | disclosed |
| US-4281189-A | Sulfonamide intermediates for adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | disclosed |
| US-4278608-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-14 | — | — | US | disclosed |
| US-4247710-A | THE 3'-HYDROXY, -BENZYLOXY, OR -HALO DERIVATIVES OF METHYL 4-((2'-HYDROXYPROPYL)OXY)PHENYLACETATE | HOFFMANN-LA ROCHE INC. (US) | 1981-01-27 | — | — | US | disclosed |
| US-4202978-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE, ANTISECRETORY, SPASMOLYTIC | HOFFMANN-LA ROCHE INC. (US) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | DRD2 1585/4885DRD3 1448/4885HTR1A 440/4885 |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | DRD2 1585/4885DRD3 1448/4885HTR1A 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.